

PRESS RELEASE
09 August 2022 08:30:00 CEST

Stockholm3 in the Swedish national guidelines for prostate cancer

In February 2022, a proposal for revised Swedish national guidelines for prostate cancer was presented and submitted for consultation. The proposal has now been adopted and the group of experts concluded that there is good evidence that Stockholm3 can select men with PSA above a certain level for further investigation and reduce the proportion of men who need to undergo MRI examination.

With around 10,000 new cases per year, prostate cancer is the most common form of cancer in Sweden and the most common cause of cancer-related death. Early detection is crucial for treatment outcome.

"We are very pleased with the conclusion of the expert panel regarding Stockholm3. The improved precision that Stockholm3 provides could contribute to saving 1000 lives annually, in Sweden alone. At the same time, unnecessary examinations that both cause patient anxiety and consume substantial healthcare resources can be avoided," says David Rosén, CEO of A3P Biomedical.

In 2018, the Ministry of Social Affairs tasked Regional Cancer Centers in Collaboration with standardizing and streamlining prostate cancer testing in the country and identifying complementary diagnostic tests. The overall goal of the guidelines is to provide a common basis for handling patients with suspected or confirmed prostate cancer, so that the variations between different regions and hospitals are minimized. A revised "National Prostate Cancer Care Program", including recommendations from the National Task Force on Organized Prostate Cancer Testing (OPT), went out for consultation in February 2022 and has now been adopted (1).

The revised guidelines state that "there is good evidence that Stockholm3 can select men with PSA above a certain level for further investigation and reduce the proportion of men who need to undergo magnetic resonance imaging" and that "the local OPT projects are well suited for continued clinical evaluation of Stockholm3".

(1) Prostate cancer - National care program 21 June 2022

For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (2).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. The study was also awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022". Multiple additional studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (2).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Region Värmland has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (2).

(2) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Attachments

[Stockholm3 in the Swedish national guidelines for prostate cancer](#)